Related Experiment Video

Updated: Jun 3, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review

Katrine B Hansen1, Tina Vilsbøll, Filip K Knop

  • 1Department of Clinical Physiology, Glostrup Hospital, University of Copenhagen, Denmark.

Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
|March 26, 2011
PubMed

Insights

New incretin mimetics offer improved type 2 diabetes treatment by activating glucagon-like peptide-1 (GLP-1) receptors, enhancing insulin secretion with low hypoglycemia risk. These agents also improve cardiovascular risk factors like weight and blood pressure.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus (T2DM) significantly reduces quality of life and life expectancy.
  • Traditional antidiabetes agents often fail to achieve optimal glycemic control and manage vascular risk factors.
  • The incretin system plays a crucial role in glucose homeostasis.

Purpose of the Study:

  • To review current clinical data on exenatide and liraglutide, two incretin mimetics.
  • To evaluate the pharmacology, efficacy, safety, and tolerability of these agents.
  • To assess their potential in managing type 2 diabetes mellitus.

Main Methods:

  • Systematic literature search of PubMed and Medline databases.
  • Inclusion of publications focusing on GLP-1 receptor agonists, exenatide, liraglutide, and T2DM.
  • Data analysis up to January 2009.

Main Results:

  • Incretin mimetics activate GLP-1 receptors, stimulating insulin secretion and synthesis.
  • These agents demonstrate a low risk of hypoglycemia due to glucose-dependent insulin release.
  • Exenatide and liraglutide show positive effects on cardiovascular risk factors, including weight loss and blood pressure reduction.

Conclusions:

  • Incretin mimetics represent a promising new class of antidiabetes drugs.
  • Exenatide and liraglutide offer therapeutic benefits for type 2 diabetes management.
  • Further evaluation of these agents is warranted for long-term outcomes and cardiovascular benefits.
Keywords:
exenatideglucagon-like peptide-1 (GLP-1)liraglutidetype 2 diabetes

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.